Pharmacodynamic Results from the CAN-001 Phase 1b Study of PP-01, an Investigational Product, intended to Mitigate Cannabis Withdrawal Syndrome PHOENIXVILLE, Pa., Nov. 18, 2024 /PRNewswire/ — PleoPharma, Inc., a privately held company focused on cannabis-related […]
Tag: PleoPharma
PLEOPHARMA, INC. Strengthens Patent Portfolio with Issuance of Two U.S. Patents
2nd Patent issued in September 2024 Patent Protection to March 2041 PHOENIXVILLE, Pa., Oct. 7, 2024 /PRNewswire/ — PleoPharma, Inc. (“PleoPharma” or the “Company), a privately held company focused on Cannabis-related health issues, announced today […]
PLEOPHARMA, INC. PARTICIPATES IN THE LIFE SCIENCES PA’S LIFE SCIENCE FUTURE CONFERENCE
PHOENIXVILLE, Pa., Sept. 19, 2024 /PRNewswire/ — PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today that their CEO, Ginger Constantine, MD, presented at the Life Sciences PA’s Life Sciences […]
A POTENTIAL FIRST IN CLASS TREATMENT
Phase 2b Study for PP-01 Met Its Primary Endpoint End of Phase 2 Meeting with FDA Completed Phase 3 Preparations Underway PHOENIXVILLE, Pa., Sept. 5, 2024 /PRNewswire/ — PleoPharma, Inc., a privately held company focused on […]
